FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Shacham Sharon 		2. Issuer Name and Ticker or Trading Symbol

Karyopharm Therapeutics Inc. [ KPTI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President & CSO
(Last)          (First)          (Middle)

C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/9/2018
(Street)

NEWTON, MA 02459
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   4/9/2018     M (1)    10000   A $0.264   723510   D    
Common Stock   4/9/2018     S (1)    10000   D $12.4829   (2) 713510   D    
Common Stock                  512143   I   By Spouse  
Common Stock                  47309   I   By GRAT   (3)
Common Stock                  47309   I   By Spouse's GRAT   (4)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $0.264   4/9/2018     M   (1)       10000      (5) 12/15/2021   Common Stock   10000   $0.00   19697   D    

Explanation of Responses:
(1)  These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
(2)  Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.64, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
(3)  These shares are held by the Sharon Shacham 2016 Qualified Annuity Interest Trust.
(4)  These shares are held by the Michael G. Kauffman 2016 Qualified Annuity Interest Trust.
(5)  This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on December 14, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Shacham Sharon
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON, MA 02459

President & CSO

Signatures
/s/ Christopher B. Primiano, Attorney-in-Fact for Sharon Shacham 4/10/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Karyopharm Therapeutics Charts.
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Karyopharm Therapeutics Charts.